US EditionGlobal First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
- Beijing Tide Pharmaceutical dosed the first patient with TRD205, a selective AT2R antagonist, in a Phase II trial for chronic post-surgical neuropathic pain on May 5, 2025 in Beijing.
- Following confirmation of safety in Phase I, the trial aims to overcome the shortcomings of existing opioid and non-opioid treatments for chronic postsurgical pain, a condition affecting about one in ten patients among the hundreds of millions undergoing surgery worldwide each year.
- TRD205 blocks AT2R-driven macrophage activation that elevates calcium influx in sensory neurons, reducing pain transmission while avoiding effects on the brain and the addiction risks associated with opioids.
- The upcoming Phase II trial aims to recruit 184 individuals with CPSP to measure changes in pain scores over a six-week timeframe, within a market anticipated to surpass $10 billion and characterized by few global AT2R-targeting contenders, including Lilly’s CFTX-1554 currently in Phase I.
- Validation of TRD205 would introduce a novel AT2R-targeted treatment option for chronic post-surgical neuropathic pain, providing an innovative, opioid-free alternative with the potential to expand into other neuropathic pain conditions worldwide.
33 Articles
33 Articles
InsideNoVA.com
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R)…
TRD205, a First-in-Class Pain Drug, Moves to Phase II with First Patient Dosed
BEIJING, May 6, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP) to enter Ph…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
